Total Payments
$654,212
2024 Payments
$122,811
Companies
42
Transactions
1,487
Medicare Patients
1,564
Medicare Billing
$221,455
Payment Breakdown by Category
Other$353,133 (54.0%)
Consulting$219,676 (33.6%)
Travel$50,266 (7.7%)
Food & Beverage$30,930 (4.7%)
Education$176.55 (0.0%)
Research$29.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $290,985 | 102 | 44.5% |
| Consulting Fee | $219,676 | 72 | 33.6% |
| Honoraria | $62,149 | 35 | 9.5% |
| Travel and Lodging | $50,266 | 187 | 7.7% |
| Food and Beverage | $30,930 | 1,078 | 4.7% |
| Education | $176.55 | 12 | 0.0% |
| Unspecified | $29.95 | 1 | 0.0% |
Payments by Type
General
$654,182
1,486 transactions
Research
$29.95
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Shire North American Group Inc | $144,047 | 149 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $98,556 | 230 | $0 (2024) |
| Pharming Healthcare, Inc. | $82,548 | 101 | $0 (2024) |
| BioCryst US Sales Co., LLC | $71,996 | 101 | $0 (2024) |
| GENZYME CORPORATION | $62,800 | 94 | $0 (2024) |
| CSL Behring | $49,249 | 136 | $0 (2024) |
| BioCryst Pharmaceuticals, Inc. | $30,147 | 19 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $28,222 | 155 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $18,198 | 73 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $16,517 | 43 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $122,811 | 242 | GENZYME CORPORATION ($29,691) |
| 2023 | $130,153 | 281 | Takeda Pharmaceuticals U.S.A., Inc. ($36,272) |
| 2022 | $67,012 | 197 | BioCryst US Sales Co., LLC ($22,710) |
| 2021 | $72,115 | 196 | Takeda Pharmaceuticals U.S.A., Inc. ($26,799) |
| 2020 | $41,299 | 124 | Pharming Healthcare, Inc. ($10,745) |
| 2019 | $100,899 | 176 | Shire North American Group Inc ($62,928) |
| 2018 | $89,684 | 165 | Shire North American Group Inc ($71,749) |
| 2017 | $30,239 | 106 | Teva Pharmaceuticals USA, Inc. ($10,705) |
All Payment Transactions
1,487 individual payment records from CMS Open Payments — Page 1 of 60
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | CUVITRU (Biological) | Food and Beverage | In-kind items and services | $8.91 | General |
| Category: IMMUNOLOGY | ||||||
| 12/24/2024 | Takeda Pharmaceuticals U.S.A., Inc. | HYQVIA (Biological) | Food and Beverage | In-kind items and services | $2.03 | General |
| Category: IMMUNOLOGY | ||||||
| 12/19/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $7.81 | General |
| Category: Immunology | ||||||
| 12/18/2024 | BioCryst US Sales Co., LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $8,175.23 | General |
| 12/18/2024 | BioCryst US Sales Co., LLC | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $403.05 | General |
| 12/18/2024 | BioCryst US Sales Co., LLC | ORLADEYO (Drug) | Food and Beverage | In-kind items and services | $0.63 | General |
| Category: Immunology | ||||||
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Consulting Fee | Cash or cash equivalent | $2,860.00 | General |
| Category: GENETIC DISEASE | ||||||
| 12/17/2024 | Takeda Pharmaceuticals U.S.A., Inc. | TAKHZYRO (Biological) | Travel and Lodging | In-kind items and services | $394.77 | General |
| Category: GENETIC DISEASE | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 12/13/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,700.00 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $383.45 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $123.68 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $17.76 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.34 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.25 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $353.57 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $228.95 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $123.14 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | CSL Behring | Haegarda (Biological) | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: Immunology | ||||||
| 12/09/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $13.21 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $20.87 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/02/2024 | Pharming Healthcare, Inc. | RUCONEST (Biological) | Food and Beverage | In-kind items and services | $29.37 | General |
| Category: BIOLOGIC | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A LONG-TERM STUDY TO ASSESS THE SAFETY AND EFFICACY OF LEBRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS | Eli Lilly and Company | $29.95 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 373 | 4,834 | $143,311 | $44,460 |
| 2022 | 10 | 358 | 6,268 | $179,779 | $63,804 |
| 2021 | 11 | 426 | 6,448 | $176,519 | $64,695 |
| 2020 | 10 | 407 | 4,888 | $149,865 | $48,495 |
Total Patients
1,564
Total Services
22,438
Medicare Billing
$221,455
Procedure Codes
39
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 75 | 104 | $23,400 | $9,224 | 39.4% |
| 95004 | Test for allergy using allergenic extract | Office | 2023 | 45 | 2,860 | $31,460 | $8,231 | 26.2% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2023 | 31 | 664 | $16,600 | $7,947 | 47.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 50 | 50 | $15,400 | $6,006 | 39.0% |
| 95117 | Professional service for multiple injections of allergen | Office | 2023 | 26 | 569 | $25,036 | $4,900 | 19.6% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2023 | 37 | 445 | $7,565 | $2,832 | 37.4% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 75 | 100 | $16,500 | $2,741 | 16.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 34 | 42 | $7,350 | $2,579 | 35.1% |
| 95165 | Professional service for preparation and provision of 1 or more antigens | Office | 2022 | 35 | 2,052 | $51,300 | $26,515 | 51.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 79 | 115 | $25,295 | $10,334 | 40.9% |
| 95004 | Test for allergy using allergenic extract | Office | 2022 | 43 | 2,758 | $30,338 | $8,574 | 28.3% |
| 95117 | Professional service for multiple injections of allergen | Office | 2022 | 36 | 652 | $28,688 | $5,769 | 20.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 37 | 37 | $11,396 | $4,487 | 39.4% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 59 | 81 | $12,945 | $2,336 | 18.0% |
| 95024 | Test for allergy using allergenic extract injected into skin | Office | 2022 | 25 | 306 | $5,202 | $2,156 | 41.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 30 | $5,078 | $1,940 | 38.2% |
| 95115 | Professional service for single injection of allergen | Office | 2022 | 17 | 225 | $7,425 | $1,305 | 17.6% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 12 | 12 | $2,112 | $390.18 | 18.5% |
| 95165 | Preparation and provision of single or multiple antigens for allergen immunotherapy | Office | 2021 | 40 | 1,555 | $38,875 | $20,529 | 52.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 86 | 121 | $23,716 | $11,609 | 48.9% |
| 95004 | Injection of allergenic extracts into skin, accessed through the skin | Office | 2021 | 45 | 3,118 | $34,298 | $10,263 | 29.9% |
| 95117 | Injection of incremental dosages of allergen, 2 or more injections | Office | 2021 | 44 | 687 | $28,183 | $5,971 | 21.2% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 43 | 43 | $13,244 | $5,762 | 43.5% |
| 95024 | Injection of allergenic extracts into skin for immediate reaction analysis | Office | 2021 | 35 | 486 | $8,262 | $3,507 | 42.4% |
| 94375 | Respiratory diagnostic testing (flow volume loop) | Office | 2021 | 58 | 79 | $11,455 | $2,347 | 20.5% |
About Dr. Daniel Soteres, MD
Dr. Daniel Soteres, MD is a Allergy healthcare provider based in Colorado Springs, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/21/2005. The National Provider Identifier (NPI) number assigned to this provider is 1679573588.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Soteres, MD has received a total of $654,212 in payments from pharmaceutical and medical device companies, with $122,811 received in 2024. These payments were reported across 1,487 transactions from 42 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($290,985).
As a Medicare-enrolled provider, Soteres has provided services to 1,564 Medicare beneficiaries, totaling 22,438 services with total Medicare billing of $221,455. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Ad
Practice Information
- Specialty Allergy
- Other Specialties Allergy
- Location Colorado Springs, CO
- Active Since 07/21/2005
- Last Updated 07/24/2008
- Taxonomy Code 207KA0200X
- Entity Type Individual
- NPI Number 1679573588
Products in Payments
- CINRYZE (Drug) $122,311
- TAKHZYRO (Biological) $106,796
- RUCONEST (Biological) $82,548
- DUPIXENT (Biological) $75,882
- ORLADEYO (Drug) $62,029
- AIRSUPRA (Drug) $23,874
- Haegarda (Biological) $18,626
- Orladeyo (Drug) $18,225
- Xolair (Biological) $13,827
- PALFORZIA (Biological) $8,812
- DUPIXENT DUPILUMAB INJECTION (Biological) $7,525
- CINQAIR (Drug) $4,941
- DUPIXENT (Drug) $4,488
- CINQAIR (Biological) $3,833
- Xhance (Drug) $3,763
- PROAIR (Drug) $2,265
- ProAir Digihaler (Drug) $1,705
- NITYR (Drug) $1,672
- FASENRA (Drug) $1,670
- EUCRISA (Drug) $1,566
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.